drugset / Trial / NCT01044537
A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus
RandomizedParallel-groupTriple-blindOther
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04937319 following single escalating oral doses in adult subjects with Type 2 Diabetes Mellitus (T2DM).
Timeline
- Start
- 2010-02
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NERIGLIATIN | Small molecule | 10 mg | Oral |
| Subject | NERIGLIATIN | Small molecule | 30 mg | Oral |
| Subject | NERIGLIATIN | Small molecule | 100 mg | Oral |
| Subject | NERIGLIATIN | Small molecule | 200 mg | Oral |
| Subject | NERIGLIATIN | Small molecule | 400 mg | Oral |